Role of apoptosis-related miRNAs in resveratrolinduced breast cancer cell death

Cell Death and Disease

Volumn 7, Issue 2, 2016, Pages

  Venkatadri, R ^a   Muni, T ^a   Iyer, A K V ^a   Yakisich, J S ^a   Azad, N ^a  

^a HAMPTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; MICRORNA; PROTEIN BCL 2; RESVERATROL; STILBENE DERIVATIVE; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

APOPTOSIS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; STILBENES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84979874564     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2016.6     Document Type: Article

References (62)

1. American Cancer Society. Cancer Facts and Figures 2015. American Cancer Society: Atlanta, GA, 2015.
2. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999; 104: 1645–1653.
3. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 36–43.
4. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002; 7: 12–19.
5. Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C. Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer. PLoS One 2014; 9: e103760.
6. Wang Z, Li W, Meng X, Jia B. Resveratrol induces gastric cancer cell apoptosis via reactive oxygen species, but independent of sirtuin1. Clin Exp Pharmacol Physiol 2012; 39: 227–232.
7. Tan TW, Tsai HR, Lu HF, HL Lin, Tsou MF, Lin YT et al. Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. Anticancer Res 2006; 26: 4361–4371.
8. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 2007; 13: 5162–5169.
9. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci 2007; 1095: 441–448.
10. Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ, Lin HY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006; 5: 2034–2042.
11. Soo E, Thakur S, Qu Z, Jambhrunkar S, Parekh HS, Popat A. Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. J Colloid Interface Sci 2016; 462: 368–374.
12. Alkhalaf M, El-Mowafy A, Renno W, Rachid O, Ali A, Al-Attyiah R. Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3dependent pathway. Arch Med Res 2008; 39: 162–168.
13. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NFkappaB. Int J Cancer 2005; 115: 74–84.
14. Mohapatra P, Preet R, Choudhuri M, Choudhuri T, Kundu CN. 5-Fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. Oncol Res 2011; 19: 311–321.
15. Sareen D, Darjatmoko SR, Albert DM, Polans AS. Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol Pharmacol 2007; 72: 1466–1475.
16. Wolfson B, Eades G, Zhou Q. Roles of microRNA-140 in stem cell-associated early stage breast cancer. World J Stem Cells 2014; 6: 591–597.
17. Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife 2014; 3: e01977.
18. Lim WK, Micklem G. MicroRNAs dysregulated in breast cancer preferentially target key oncogenic pathways. Mol Biosyst 2011; 7: 2571–2576.
19. Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res 2011; 55: 1219–1229.
20. Jiang L, Tao C, He A, He X. Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol 2014; 12: 383.
21. Sethi S, Li Y, Sarkar FH. Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets 2013; 14: 1167–1174.
22. Li Y, Kong D, Ahmad A, Bao B, Dyson G, Sarkar FH. Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. Epigenetics 2012; 7: 940–949.
23. Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, Yong Z et al. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res 2012; 14: R80.
24. Alayev A, Berger SM, Kramer MY, Schwartz NS, Holz MK. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J Cell Biochem 2015; 116: 450–457.
25. Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells 2013; 35: 219–225.
26. Shi Y, Yang S, Troup S, Lu X, Callaghan S, Park DS et al. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep 2011; 25: 1713–1719.
27. Ferraz da Costa DC, Casanova FA, Quarti J, Malheiros MS, Sanches D, Dos Santos PS et al. Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells. PLoS One 2012; 7: e48746.
28. Olsson M, Zhivotovsky B. Caspases and cancer. Cell Death Differ 2011; 18: 1441–1449.
29. Clément MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92: 996–1002.
30. Delmas D, Rébé C, Lacour S, Filomenko R, Athias A, Gambert P et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a deathinducing signaling complex in colon cancer cells. J Biol Chem 2003; 278: 41482–41490.
31. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010; 5: e15627.
32. Quoc Trung L, Espinoza JL, Takami A, Nakao S. Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One 2013; 8: e55183.
33. Hahnvajanawonga C, Ketnimita S, Boonyanugomola W, Pattanapanyasatd K, Chamgramole Y, Sripae B et al. Inhibition of cell cycle progression and apoptotic activity of resveratrol in human intrahepatic cholangiocarcinoma cell lines. Asian Biomed 2011; 5: 775–785.
34. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellón EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007; 28: 282–293.
35. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006; 5: 621–629.
36. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 2002; 64: 1375–1386.
37. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770–1783.
38. Dong F, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ et al. Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in nonsmall cell lung cancer cells. Cancer Biol Ther 2006; 5: 165–170.
39. Mani S, Wang C, Wu K, Francis R, Pestell R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 2000; 9: 1849–1870.
40. Adams BD, Guttilla IK, White BA. Involvement of microRNAs in breast cancer. Semin Reprod Med 2008; 26: 522–536.
41. Sun X, Luo S, He Y, Shao Y, Liu C, Chen Q et al. Screening of the miRNAs related to breast cancer and identification of its target genes. Eur J Gynaecol Oncol 2014; 35: 696–700.
42. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008; 15: 341–355.
43. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deepsequencing data. Nucleic Acids Res 2011; 39: D152–D157.
44. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: D154–D158.
45. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: D140–D144.
46. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res 2004; 32: D109–D111.
47. Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S et al. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actinregulatory proteins FHOD1 and PPM1F. Mol Cell Biol 2012; 32: 633–651.
48. Basu A, Jiang X, Negrini M, Haldar S. MicroRNA-mediated regulation of pancreatic cancer cell proliferation. Oncol Lett 2010; 1: 565–568.
49. Chen BB, Chen XB, Bie LY, Mu Y, Wang HL, Lv HF et al. Decreased expression of miR-542-3p exerts growth inhibitory functions in esophageal cancer. J Can Res Ther 2015; 11: 24–28.
50. Cai J, Zhao J, Zhang N, Xu X, Li R, Yi Y et al. MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J Biol Chem 2015; 290: 24678–24688.
51. Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 2011; 4: 17.
52. Yoon S, Choi YC, Lee S, Jeong Y, Yoon J, Baek K. Induction of growth arrest by miR-542-3p that targets surviving. FEBS Lett 2010; 584: 4048–4052.
53. Nassirpour R, Mehta PP, Yin MJ. miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One 2013; 8: e79655.
54. Ergun S, Ulasli M, Igci YZ, Igci M, Kirkbes S, Borazan E et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 2015; 42: 497–505.
55. Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T et al. MiR-199a-5p is negatively associated with the malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatology 2015; 62: 1132–1144.
56. He XJ, Ma YY, Yu S, Jiang XT, Lu YD, Tao L et al. Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer 2014; 14: 218.
57. Yi H, Liang B, Jia J, Liang N, Xu H, Ju G et al. Differential roles of miR-199a-5p in radiationinduced autophagy in breast cancer cells. FEBS Lett 2013; 587: 436–443.
58. Li Q, Yao Y, Eades G, Liu Z, Zhang Y, Zhou Q. Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene 2014; 33: 2589–2600.
59. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. miR-125b targets ARID3B in breast cancer cells. Cell Struct Funct 2012; 37: 27–38.
60. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010; 107: 8231–8236.
61. Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 2014; 33: 702–712.
62. Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernandez-Losa J et al. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. PLoS One 2013; 8: e76247.